Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura™ (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular Degeneration

NCT05571267 is registered in ClinicalTrials.gov with IVERIC bio, Inc. as lead sponsor.

NCT NCT05571267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05571267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura™ (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
IVERIC bio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 20, 2016
Completion date
April 24, 2018
Enrollment
1 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration